Industry sponsor intelligence

Fujian Shengdi Pharmaceutical Co., Ltd.Clinical Pipeline.

Lead-sponsor view of Fujian Shengdi Pharmaceutical Co., Ltd.'s indexed peptide studies, development phases, active programs, completed work and recent registry changes.

Total: 2
Recruiting: 0
Active: 0
Completed: 2
Results posted: 0
Avg enrollment: 474

Pipeline overview

Programs by phase and activity.

Velocity

Fujian Shengdi Pharmaceutical Co., Ltd. trials by start year

Study start year · indexed snapshot

Development

Trials by phase

2phase labels

Early Phase 10

Phase 11

Phase 20

Phase 31

Phase 40

Product	Studies	Early / I	Phase II	Phase III	Phase IV	Active
Semaglutide →	1	0	0	1	0	0
Dulaglutide →	1	1	0	0	0	0

Active peptide trials

In motion now.

No studies in this snapshot.

Completed trials

Finished registry records.

NCT IDStudyPhase / statusEnrollmentUpdated

NCT06649344

A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes

Fujian Shengdi Pharmaceutical Co., Ltd. · Type 2 Diabetes

Phase 3

Completed

884

2026-07

NCT05516966

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Subcutaneous Injections of HRS9531 in Patients With Type 2 Diabetes Mellitus

Fujian Shengdi Pharmaceutical Co., Ltd. · Diabetes Mellitus, Type 2

Phase 1

Completed

2024-11

Search sponsor records

All Fujian Shengdi Pharmaceutical Co., Ltd. studies.

This page groups studies where Fujian Shengdi Pharmaceutical Co., Ltd. is listed as the lead industry sponsor. Collaborator-only records are not included in the count.